Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma

Affiliations

¹ Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
² Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: rinib2@ccf.org.

Comment

Idir Ouzaid et al. Eur Urol. 2014 Mar.

. 2014 Mar;65(3):667-8.

doi: 10.1016/j.eururo.2013.11.023.

¹ Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
² Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: rinib2@ccf.org.

No abstract available

Comment on

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Motzer RJ, et al. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989. N Engl J Med. 2013. PMID: 23964934 Clinical Trial.